Öztürk Şahin Burcu, Özen Şennur, Baydar Toprak Oya, Köktürk Nurdan, Kitapçı Mehmet Tevfik
Department of Pulmonary Medicine, Gazi University, Faculty of Medicine, Ankara, Turkey.
Department of Pulmonary Medicine, Delta Hospital, İstanbul, Turkey.
Thorac Res Pract. 2023 Jan;24(1):29-33. doi: 10.5152/ThoracResPract.2022.22045.
It is accepted that the only way to end severe acute respiratory syndrome coronavirus 2 epidemic is through community vaccination. The frequency and clinical features of infection after vaccination are not known clearly. The aim of this study is to determine the frequency and clinical features of coronavirus disease 2019 seen after either the first or second dose of CoronaVac vaccination in healthcare workers and their relatives.
This is a cross-sectional retrospective survey study. The study was carried out in 2013 volunteers, including 1903 (94.5%) healthcare workers and 110 (5.5%) relatives of healthcare workers. The frequency and clinical features of coronavirus disease 2019 before and after the first or second dose of CoronaVac vaccination were retrospectively evaluated using an online questionnaire conducted in July 2021.
A total of 2013 people, 1312 women and 701 men, participated in the study. Of these individuals, 245 (12.1%) were polymerase chain reaction positive for coronavirus disease 2019 before vaccination. Of this group, 185 (75.5% of polymerase chain reaction positives and 9.1% of the whole population) received home-based therapy, while 38 (15.5%) received hospital admission. Asymptomatic polymerase chain reaction positivity before vaccination was seen in 22 (9%) individuals. There were 177 (8.8%) participants who developed polymerase chain reaction positivity at any time after vaccination. In 129 (72.8%) of these participants, polymerase chain reaction positivity occurred 21 days after the second dose of vaccine. While the number of patients hospitalized before vaccination was 38 (15.5% of the polymerase chain reaction positivity group and 1.89% of the general population), the number of patients hospitalized after the vaccination was 17 (10.1% of the polymerase chain reaction positivity group and 0.80% of the general population). The decrease in hospitalization proportion was statistically significant (P = .002).
The frequency of coronavirus disease 2019, severe illness, and hospitalization rates were found to be lower in postvaccination period. The vaccine is effective in preventing coronavirus disease 2019 and severe disease.
人们公认，结束严重急性呼吸综合征冠状病毒2疫情的唯一途径是通过社区疫苗接种。疫苗接种后感染的频率和临床特征尚不清楚。本研究的目的是确定医护人员及其亲属在接种第一剂或第二剂科兴新冠疫苗后出现的2019冠状病毒病的频率和临床特征。
这是一项横断面回顾性调查研究。该研究在2013名志愿者中开展，其中包括1903名（94.5%）医护人员和110名（5.5%）医护人员的亲属。通过2021年7月进行的在线问卷调查，对第一剂或第二剂科兴新冠疫苗接种前后2019冠状病毒病的频率和临床特征进行回顾性评估。
共有2013人参与研究，其中女性1312人，男性701人。在这些个体中，245人（12.1%）在接种疫苗前2019冠状病毒病聚合酶链反应呈阳性。在这一组中，185人（聚合酶链反应阳性者的75.5%，全体人群的9.1%）接受居家治疗，而38人（15.5%）入院治疗。22名（9%）个体在接种疫苗前聚合酶链反应呈无症状阳性。有177名（8.8%）参与者在接种疫苗后的任何时间出现聚合酶链反应阳性。在这些参与者中，129人（72.8%）在接种第二剂疫苗21天后聚合酶链反应呈阳性。接种疫苗前住院的患者有38人（占聚合酶链反应阳性组的15.5%，占总体人群的1.89%），接种疫苗后住院的患者有17人（占聚合酶链反应阳性组的10.1%，占总体人群的0.80%）。住院比例的下降具有统计学意义（P = .002）。
发现接种疫苗后2019冠状病毒病的频率、重症和住院率较低。该疫苗在预防2019冠状病毒病和重症方面有效。
